Maximum Strength Jointcare: A scientifically – advanced, once-a-day formulation that not only helps build and maintain healthy joints and cartilage, but also helps relieve joint discomfort. The new, improved formula offers smooth, steady, extended release of three powerful compounds for all day joint comfort.
Molecular and genetic alterations that cause tumors and drive the course of disease may someday explain the differences in incidence and mortality between African American and European American breast cancer patients. This is the conclusion of a literature review by a research team at Roswell Park Cancer Institute (RPCI) led by Christine B. Ambrosone, PhD, Chair of Epidemiology at RPCI. Results of the study are published in the September edition of Cancer Research.
UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II clinical trials next year.
Blackwell Publishing is set to break into an exciting new area of clinical psychiatry with its new journal – Early Intervention in Psychiatry. The journal will be launched at the IEPA Conference in Birmingham in October 2006, and will publish its inaugural issue in February 2007.
One in four U.S. adults suffer from a diagnosable mental disorder, yet they face barriers to equal access to treatment and preventive health services, public health experts said today at a forum releasing new research examining the impact of mental illness on the nation’s health from the October 2006 issue of the American Journal of Public Health.
Researchers will report results of a follow-on study of the first non-invasive, diabetes-screening device that was able to significantly outperform the fasting plasma glucose (FPG) test and the A1C test for identifying diabetes and pre-diabetes in individuals with one or more known risk factors for the disease. Presented at the 2006 Scientific Assembly of the American Academy of Family Physicians, held here, the study showed a prototype of the device was able to identify 29% more patients than the FPG test and 17% more patients than the A1C test. Both the FPG and A1C are blood tests used to screen and evaluate patients at risk for diabetes.
Pfizer Inc said today that the European Commission has approved Champix(R) (varenicline), a novel pill for smoking cessation in adults. In addition, because smokers often need considerable support to quit successfully, Champix will be available with a patient support plan which smokers can customize to address their individual behavioral triggers as they try to quit smoking.
The potent cancer drug Gleevec, used to combat leukemia and some gastrointestinal cancers, may be useful in treating rheumatoid arthritis, according to a team of researchers at the Stanford University School of Medicine. Their findings will be published in the October issue of the Journal of Clinical Investigation.
Some people out there wonder why people pay out money on expensive contact lenses or expensive glasses. If you?ve never worn glasses or contact lenses, then chances are that you have good eyesight. In contrast, those that don?t have good vision will need to get either contact lenses or glasses in order to have near perfect vision.
If you someday become diagnosed with skin cancer and survive, one of the most worrisome issues you will face will be preventing a recurrence of the cancer. After successful treatment, your doctor will continue to schedule regular follow-up appointments to ensure that you remain skin cancer-free. Even regular medical attention is no substitute for exercising good skin care habits.